Takeda Pharmaceutical

Seattle Genetics, Millennium, Ventana collaborate on companion diagnostic test for Adcetris

Friday, April 13, 2012 12:37 PM

Seattle Genetics and Millennium, a subsidiary of Takeda Pharmaceutical, have formed a collaboration with Ventana Medical Systems, a member of the Roche Group, through which Ventana will seek to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with Adcetris based on CD30 expression levels in their tissue specimens.

More... »


Takeda to acquire URL Pharma

Wednesday, April 11, 2012 09:53 AM

Takeda America Holdings (a subsidiary of Takeda Pharmaceutical) has agreed to acquire URL Pharma, a Philadelphia-based specialty pharmaceutical company, for an upfront payment of $800 million and future performance-based contingent earn out payments. URL Pharma will be managed by Takeda Pharmaceuticals USA of Deerfield, Ill.

More... »


Takeda joins SGC, funds drug research

Friday, April 6, 2012 11:34 AM

Takeda Pharmaceutical has joined the Structural Genomics Consortium (SGC), based at the Universities of Toronto and Oxford, England, to fund collective drug research aimed at bringing new, more effective medicines to market faster.

More... »

Takeda establishes development center in China

Friday, February 10, 2012 09:54 AM

Takeda Pharmaceutical has established the Takeda Shanghai Development Center ("TSDC") within the Shanghai-based Takeda (China) Holdings (TCH), a wholly owned subsidiary of Takeda.

More... »

Takeda to cut 2,800 jobs as it absorbs Nycomed

Wednesday, January 18, 2012 12:21 PM

Osaka, Japan-based Takeda Pharmaceutical plans to consolidate its R&D site operations and cut its workforce by 2,800 to integrate legacy Nycomed operations, strengthen its presence in more than 70 countries, adapt to changing market conditions and maintain a focus on growth through innovation and culture.

More... »

Takeda to integrate two subsidiaries in California

Wednesday, December 21, 2011 01:47 PM

Takeda Pharmaceutical will integrate two wholly-owned subsidiaries, Takeda San Diego (TSD) and Takeda San Francisco (TSF) on January 1, 2012. TSD will become the surviving company and change its name to Takeda California (TCAL) the same day. Keith Wilson, current president of TSD, will become the president of the new company.

More... »

Takeda to acquire Intellikine for $190 million

Wednesday, December 21, 2011 01:31 PM

Takeda Pharmaceutical and Intellikine have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash. Takeda expects that the transaction will be finalized in January 2012. Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.

More... »

Takeda acquires Nycomed for $13.7 billion

Tuesday, August 2, 2011 12:50 PM

Japanese drug maker Takeda Pharmaceutical secured EU approval for its $13.68 billion acquisition of privately owned Nycomed to reinforce its presence in emerging markets, according to Reuters.

More... »

Millenium expands on cancer treatment Velcade

Thursday, April 28, 2011 12:32 PM

Cambridge-based pharmaceutical company Millennium and their parent company Takeda Pharmaceutical, based in Japan, report they have submitted two supplemental new drug applications (NDAs) to the FDA for Velcade, a cancer treatment, according to Mass High Tech.

More... »

Takeda, Amgen phase III motesanib trial fails

Friday, April 1, 2011 10:53 AM

Amgen, Takeda Pharmaceutical, and Millennium, a division of Takeda, announced unfavorable results from the MONET1 pivotal phase III trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer (NSCLC). The trial did not meet its primary objective of demonstrating an improvement in overall survival.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs